These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 23734858)

  • 21. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.
    Rosenthal RN; Ling W; Casadonte P; Vocci F; Bailey GL; Kampman K; Patkar A; Chavoustie S; Blasey C; Sigmon S; Beebe KL
    Addiction; 2013 Dec; 108(12):2141-9. PubMed ID: 23919595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.
    Barry DT; Savant JD; Beitel M; Cutter CJ; Moore BA; Schottenfeld RS; Fiellin DA
    J Addict Med; 2012 Dec; 6(4):274-9. PubMed ID: 23041680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of outcome after short-term stabilization with buprenorphine.
    Hillhouse M; Canamar CP; Ling W
    J Subst Abuse Treat; 2013 Mar; 44(3):336-42. PubMed ID: 23021099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
    Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
    Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
    Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
    N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterizing opioid withdrawal during double-blind buprenorphine detoxification.
    Dunn KE; Saulsgiver KA; Miller ME; Nuzzo PA; Sigmon SC
    Drug Alcohol Depend; 2015 Jun; 151():47-55. PubMed ID: 25823907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
    Pélissier F; Rougé Bugat ME; Nubukpo P; Franchitto N
    J Clin Psychopharmacol; 2016 Feb; 36(1):100-3. PubMed ID: 26658085
    [No Abstract]   [Full Text] [Related]  

  • 30. Single high-dose buprenorphine for opioid craving during withdrawal.
    Ahmadi J; Jahromi MS; Ghahremani D; London ED
    Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.
    Tompkins DA; Smith MT; Mintzer MZ; Campbell CM; Strain EC
    J Pharmacol Exp Ther; 2014 Feb; 348(2):217-26. PubMed ID: 24227768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized pilot trial of Web-based cognitive-behavioral therapy adapted for use in office-based buprenorphine maintenance.
    Shi JM; Henry SP; Dwy SL; Orazietti SA; Carroll KM
    Subst Abus; 2019; 40(2):132-135. PubMed ID: 30714880
    [No Abstract]   [Full Text] [Related]  

  • 33. Commentary on Ling et al. (2013): is there a role for psychotherapy in the treatment of opioid dependence?
    Petry NM
    Addiction; 2013 Oct; 108(10):1799-800. PubMed ID: 24033782
    [No Abstract]   [Full Text] [Related]  

  • 34. Pain is not associated with worse office-based buprenorphine treatment outcomes.
    Fox AD; Sohler NL; Starrels JL; Ning Y; Giovanniello A; Cunningham CO
    Subst Abus; 2012; 33(4):361-5. PubMed ID: 22989279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.
    Dunn KE; Weerts EM; Huhn AS; Schroeder JR; Tompkins DA; Bigelow GE; Strain EC
    Addict Biol; 2020 Jan; 25(1):e12680. PubMed ID: 30295400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.
    Wiegand TJ
    J Med Toxicol; 2016 Mar; 12(1):64-70. PubMed ID: 26574020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
    Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V
    Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
    Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
    Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.